Publication | Open Access

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Hematological MalignancyMedicineImmunologyClinical TrialsHematologyImmune Checkpoint InhibitorImmunotherapyOncologyTreatment-naive Multiple MyelomaHealth Sciences